IRIS
GIORGIO, Carmine
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.511
AS - Asia 3.784
EU - Europa 3.606
SA - Sud America 501
AF - Africa 244
Continente sconosciuto - Info sul continente non disponibili 197
Totale 14.843
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.331
SG - Singapore 1.226
IT - Italia 1.156
CN - Cina 1.029
VN - Vietnam 640
FI - Finlandia 456
IE - Irlanda 427
DE - Germania 414
BR - Brasile 389
SE - Svezia 374
HK - Hong Kong 240
FR - Francia 166
ZA - Sudafrica 154
IN - India 151
GB - Regno Unito 138
BD - Bangladesh 134
NL - Olanda 97
TR - Turchia 95
UA - Ucraina 81
CA - Canada 78
RU - Federazione Russa 75
BE - Belgio 52
AR - Argentina 45
CI - Costa d'Avorio 43
MX - Messico 41
ID - Indonesia 35
JP - Giappone 32
AT - Austria 28
IQ - Iraq 26
KR - Corea 25
ES - Italia 23
CZ - Repubblica Ceca 21
PH - Filippine 21
TH - Thailandia 21
PK - Pakistan 20
PL - Polonia 20
EC - Ecuador 18
VE - Venezuela 15
JO - Giordania 14
LT - Lituania 14
SA - Arabia Saudita 13
RO - Romania 12
CO - Colombia 9
CR - Costa Rica 9
EG - Egitto 9
AL - Albania 8
CL - Cile 8
JM - Giamaica 8
MA - Marocco 8
TT - Trinidad e Tobago 8
CH - Svizzera 7
DK - Danimarca 7
HN - Honduras 7
HU - Ungheria 7
TN - Tunisia 7
UZ - Uzbekistan 7
KE - Kenya 6
KG - Kirghizistan 6
MY - Malesia 6
PA - Panama 6
PY - Paraguay 6
BO - Bolivia 5
ET - Etiopia 5
GT - Guatemala 5
LB - Libano 5
TW - Taiwan 5
AE - Emirati Arabi Uniti 4
CW - ???statistics.table.value.countryCode.CW??? 4
NI - Nicaragua 4
PE - Perù 4
PS - Palestinian Territory 4
BH - Bahrain 3
DZ - Algeria 3
EU - Europa 3
HR - Croazia 3
IL - Israele 3
NP - Nepal 3
OM - Oman 3
RS - Serbia 3
SN - Senegal 3
SV - El Salvador 3
AZ - Azerbaigian 2
BB - Barbados 2
BG - Bulgaria 2
BS - Bahamas 2
GP - Guadalupe 2
IR - Iran 2
KZ - Kazakistan 2
LK - Sri Lanka 2
LV - Lettonia 2
NO - Norvegia 2
PT - Portogallo 2
QA - Qatar 2
SC - Seychelles 2
SI - Slovenia 2
A1 - Anonimo 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BM - Bermuda 1
Totale 14.637
Salva come PNG Salva come JPEG
Città #
Dallas 1.625
Singapore 666
Ashburn 627
San Jose 490
Dublin 427
Chandler 393
Parma 377
Santa Clara 366
Ann Arbor 282
Beijing 233
Hong Kong 221
Ho Chi Minh City 196
Munich 179
Boardman 174
Council Bluffs 168
Johannesburg 149
Hanoi 145
Dearborn 143
Los Angeles 113
New York 111
Helsinki 105
Shanghai 98
Jacksonville 87
Nanjing 76
Hefei 75
Izmir 71
Lauterbourg 68
Princeton 60
Bremen 59
Bologna 58
Wilmington 55
Milan 49
Chicago 44
Abidjan 43
Brussels 41
São Paulo 41
Columbus 38
Buffalo 36
San Mateo 31
Shenyang 31
Frankfurt am Main 30
London 30
Haiphong 29
Moscow 28
Bangalore 27
Guangzhou 27
Turku 27
Kunming 26
Toronto 24
Da Nang 23
Rome 23
Hillsboro 22
Modena 22
North Bergen 22
Orem 22
Tokyo 22
Brescia 21
Jakarta 20
Phoenix 20
Vienna 20
Jinan 19
Lubbock 19
Montreal 19
Seoul 19
Nanchang 18
Nuremberg 18
Seattle 18
Des Moines 17
Düsseldorf 17
Fremont 17
Hebei 17
Houston 17
The Dalles 17
Reggio Emilia 16
Rio de Janeiro 16
Washington 16
Changsha 15
Grafing 15
Mexico City 15
Naples 15
Atlanta 14
Bengaluru 14
Jiaxing 14
Woodbridge 14
Brooklyn 13
Hangzhou 13
Tianjin 13
Amman 12
Belo Horizonte 12
Dalmine 12
Denver 12
Amsterdam 11
Ankara 11
Boston 11
Brno 11
Chennai 11
Manchester 11
Münster 11
Piacenza 11
Warsaw 11
Totale 9.318
Salva come PNG Salva come JPEG
Nome #
1,8-Naphthyridines IX. Potent anti-inflammatory and/or analgesic activity of a new group of substituted 5 amino[1,2,4]triazolo[4,3-a] [1,8]naphthyridine-6 carboxamides, of some their Mannich base derivatives and of one novel substituted 5-amino-10-oxo-10Hpyrimido[1,2-a [1,8]naphthyridine-6-carboxamide derivative 1.731
A Pharmacological Investigation of Eph-Ephrin Antagonism in Prostate Cancer: UniPR1331 Efficacy Evidence 308
Metabolic Soft Spot and Pharmacokinetics: Functionalization of C-3 Position of an Eph–Ephrin Antagonist Featuring a Bile Acid Core as an Effective Strategy to Obtain Oral Bioavailability in Mice 288
Pharmacological characterization of second generation FXR agonists as effective EphA2 antagonists: A successful application of target hopping approach 273
Discovery of a new 1-(phenylsulfonyl)-1H-indole derivative targeting the EphA2 receptor with antiproliferative activity on U251 glioblastoma cell line 270
Targeting the Eph/ephrin system as anti-inflammatory strategy in IBD 265
Inhibition of Eph/ephrin interaction with the small molecule UniPR500 improves glucose tolerance in healthy and insulin-resistant mice 248
Development of an orally bioavailable small molecule targeting Eph-ephrin system: in vitro and in vivo anticancer activity. 234
Pharmacological evaluation of new bioavailable small molecules targeting Eph/ephrin interaction 233
Drug-gut microbiota metabolic interactions: the case of UniPR1331, selective antagonist of the Eph-ephrin system, in mice 228
Optimization of EphA2 antagonists based on a lithocholic acid core led to the identification of UniPR505, a new 3α-carbamoyloxy derivative with antiangiogenetic properties 227
Amino acid conjugates of lithocholic acid as antagonists of the EphA2 receptor. 226
Increased Mucosal Thrombin is Associated with Crohn's Disease and Causes Inflammatory Damage through Protease-activated Receptors Activation 224
Combining ligand- and structure-based approaches for the discovery of new inhibitors of the EPHA2-ephrin-A1 interaction 216
Discovery and development of Eph-ephrin antagonists endowed with antiangiogenic properties 213
UniPR129 is a competitive small molecule Eph-ephrin antagonist blocking in vitro angiogenesis at low micromolar concentrations. 209
Polyphenol rich botanicals used as food supplements interfere with EphA2-ephrinA1 system. 200
Discovery and development of small molecules targeting Eph-ephrin system in glioblastoma: an academic history 198
Multi-Target CFTR Modulators Endowed with Multiple Beneficial Side Effects for Cystic Fibrosis Patients: Toward a Simplified Therapeutic Approach 196
Enhanced photosensitizing properties of protein bound curcumin 194
Impact of S1P mimetics on mesenteric ischemia/reperfusion injury 194
Design and structure-activity relationship of amino acid derivatives of lithocholic acid as novel EphA2 antagonists 193
Structure–Activity Relationships and Mechanism of Action of Eph–ephrin Antagonists: Interaction of Cholanic Acid with the EphA2 Receptor 189
NEW EPH ANTAGONISTS DISCRIMINATING BETWEEN EPH-AS AND EPH-BS CLASSES 188
Ephrin receptor type-A2 (EphA2) targeting in cancer: a patent review (2018-present) 185
Hypericin - apomyoglobin an enhanced photosensitizer complex for the treatment of tumor cells 183
Lithocholic acid is an Eph-ephrin ligand interfering with Eph-kinase activation 182
Probing the effects of MR120 in preclinical chronic colitis: A first-in-class anti-IBD agent targeting the CCL20/CCR6 axis 181
UniPR1331: small Eph/ephrin antagonist beneficial in intestinal inflammation by interfering with type-B signaling 179
Protein-Protein Interaction Inhibitors Targeting the Eph-Ephrin System with a Focus on Amino Acid Conjugates of Bile Acids 179
270 Discovery, development and optimization of low molecular weight EPH–ephrin protein–protein inhibitors 178
1-Methyl and 1-(2-hydroxyalkyl)-5-(3-alkyl/cycloalkyl/phenyl/naphthylureido)-1H-pyrazole-4-carboxylic acid ethyl esters as potent human neutrophil chemotaxis inhibitors 177
Discovery of small-molecule targeting the CCL20/CCR6 axis as first-in-class inhibitors for inflammatory bowel diseases 170
Perturbation of The EphA2-EphrinA1 System in Human Prostate Cancer Cells by Colonic (Poly)phenol Catabolites 168
Development of 3-oxo-cholenic derivatives as Eph antagonists able to block in vitro angiogenesis 168
Multiple approaches for the discovery and development of small molecules targeting Eph-ephrin protein-protein interaction 168
Molecular Determinants of EphA2 and EphB2 Antagonism Enable the Design of Ligands with Improved Selectivity 166
Benzofuran-2-Carboxamide Derivatives as Immunomodulatory Agents Blocking the CCL20-Induced Chemotaxis and Colon Cancer Growth 166
Eph/ephrin targeting with a small molecule improves glucose tolerance in healthy and insulin-resistant mice 166
Biochemical characterization of EphA2 antagonists with improved physico-chemical properties by cell-based assays and surface plasmon resonance analysis 166
Botanicals used as food supplements interfering with EphA2-ephrinA1 system: a screening study 165
Exploiting Free-Energy Minima to Design Novel EphA2 Protein-Protein Antagonists: From Simulation to Experiment and Return 161
PHARMACOLOGICAL CHARACTERIZATION OF NEW COMPOUNDS AIMED AT INHIBITING EPH-EPHRIN INTERACTION IN GLIOBLASTOMA 159
Δ5-Cholenoyl-amino acids as selective and orally available antagonists of the Eph-ephrin system 159
Evaluation of the anti-tumor activity of small molecules targeting eph/ephrins in apcmin j mice 159
Structure activity relationship of new EphA2 ligands 154
Design and structure-activity relationships of amino acid derivatives of lithocholic acid as novel EphA2 receptor antagonists. 154
Combining pharmacology, target hopping and computational medicinal chemistry to discover novel scaffold targeting EPH-ephrin interaction. 154
Synthesis of new 5,6-dihydrobenzo[h]quinazoline 2,4-diamino substituted and antiplatelet/antiphlogistic activities evaluation. 153
Metadynamics for perspective drug design: Computationally driven synthesis of new protein-protein interaction inhibitors targeting the EphA2 receptor 153
Discovery and development of low molecular weight Eph-ephrin protein-protein inhbi-tors endowed with antiangiogenic activity 151
Target-hopping: a useful approach to identify novel Eph receptor antagonists 149
Discovery of natural extracts interfering with EphA2-ephrinA1 system 149
The ellagitannin colonic metabolite urolithin D selectively inhibits EphA2 phosphorylation in prostate cancer cells 147
Target Hopping as a Useful Tool for the Identification of Novel EphA2 Protein–Protein Antagonists 146
UniPR1331, a small molecule targeting Eph/ephrin interaction, prolongs survival in glioblastoma and potentiates the effect of antiangiogenic therapy in mice 146
Effects of CCL20/CCR6 modulators in a T cell adoptive transfer model of colitis 143
Eph-ephrin antagonism in tumor angiogenesis and growth: UniPR1331 preclinical evidence. 141
The rare bile acid isoallolithocholic acid (IALCA) is an EphA2 antagonist sparing FXR and TGR5 receptors 138
Synthesis and Structure-Activity Relationships of Amino Acid Conjugates of Cholanic Acid as Antagonists of the EphA2 Receptor. 138
Lithocholic acid competitively inhibitis EphA2-ephrinA1 binding: pharmacological and structural considerations. 132
Lithocholic Acid Is an Eph-ephrin Ligand Interfering with Eph-kinase Activation. 132
Recombinant Alpha-1 Antitrypsin as Dry Powder for Pulmonary Administration: A Formulative Proof of Concept 131
Antinflammatory properties of novel 5-amino[1,2,4]-triazolo[4,3-a][1,8]naphthyridines-caroboxamides derivatives 131
Lithocholic acid competitively inhibits EphA2-ephrinA1 binding: pharmacological and structural considerations. 128
Ocotea quixos Lam. essential oil: In vitro and in vivo investigation on its anti-inflammatory properties. 125
Drug discovery: In silico dry data can bypass biological wet data? 122
Investigation on the anti-inflammatory properties of Ocotea quixos Lam. essential oil. 121
Therapeutic perspectives of Eph–ephrin system modulation 120
Su1816–Protection by Ccr6 Blockade in a Murine Model of Crohn’s Disease 114
UNIPR1331: SMALL EPH/EPHRIN ANTAGONIST BENEFICIAL IN INTESTINAL INFLAMMATION BY INTERFERING WITH TYPE-B SIGNALLING 109
Ephrin or not? Six tough questions on Eph targeting 109
Studies on the antiplatelet and antithrombotic profile of anti-inflammatory coumarin derivatives 99
In vitro and in vivo efficacy of an orally bioavailable antagonist of Eph-ephrin system in tumor angiogenesis and growth 96
Dual targeting of EphAs and KDR axis hampers VEGF-induced angiogenesis and glioma stem cell replication 95
Targeting Eph/ephrin system in cancer therapy 95
Protection by Eph/ephrin antagonists against TNBS-induced colitis: effects of the route of administration 79
Target validation of natural compounds: Perillaldehyde case study 52
Morphological and molecular analysis of PKCε expression in dorsal root ganglia in a rat model of fibromyalgia 50
Ricerca e caratterizzazione di ligandi per efrine chinasi coinvolte nei processi tumorali 23
Dequalinium-based bitopic ligands uncover distinct pharmacological modulation of muscarinic receptors 23
High thrombin activity associated with crohn's disease induces microbiota pathogenicity contributing to mucosal inflammation 11
Totale 14.843
Salva come PNG Salva come JPEG
Categoria #
all - tutte 45.307
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 45.307
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022357 0 0 0 0 36 27 45 44 36 40 18 111
2022/20231.650 161 172 77 133 185 175 42 89 505 27 56 28
2023/2024693 44 41 36 35 47 129 67 53 27 47 75 92
2024/20252.333 98 115 132 117 251 243 176 149 296 200 204 352
2025/20266.273 436 714 1.592 426 642 282 484 180 672 408 256 181
2026/20271.120 171 241 338 359 11 0 0 0 0 0 0 0
Totale 14.843